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Evolving treatment implementation among HIV–
infected pregnant women and their partners: 
results from a national surveillance study in Italy, 
2001–2015
Background The current global and national indications for 
antiretroviral treatment (ART, usually triple combination ther-
apy) in adolescent and adults, including pregnant women, rec-
ommend early ART before immunologic decline, pre–exposure 
chemoprophylaxis (PrEP), and treatment of HIV–negative part-
ners in serodiscordant couples. There is limited information on 
the implementation of these recommendations among preg-
nant women with HIV and their partners.
Methods The present analysis was performed in 2016, using 
data from clinical records of pregnant women with HIV, fol-
lowed between 2001 and 2015 at hospital or university clinics 
within a large, nationally representative Italian cohort study. 
The study period was divided in three intervals of five years 
each (2001–2005, 2006–2010, 2011–2015), and the analysis 
evaluated temporal trends in rates of HIV diagnosis in preg-
nancy, maternal antiretroviral treatment at conception, preva-
lence of HIV infection among partners of pregnant women with 
HIV, and proportion of seronegative and seropositive male part-
ners receiving antiretroviral treatment.
Results The analysis included 2755 pregnancies in women 
with HIV. During the three time intervals considered the rate 
of HIV diagnosis in pregnancy (overall 23.3%), and the distri-
bution of HIV status among male partners (overall 48.7% HIV–
negative, 28.6% HIV–positive and 22.8% unknown) remained 
substantially unchanged. Significant increases were observed 
in the proportion of women with HIV diagnosed before preg-
nancy who were on antiretroviral treatment at conception (from 
62.0% in 2001–2005 to 81.3% in 2011–2015, P < 0.001), and 
in the proportion of HIV–positive partners on antiretroviral 
treatment (from 73.3% in 2001–2005 to 95.8% in 2011–2015, 
P = 0.002). Antiretroviral treatment was administered in 99.1% 
of the pregnancies that did not end early because of miscarriage, 
termination, or intrauterine death, and in 75.3% of those not 
ending in a live birth. No implementation of antiretroviral treat-
ment was introduced among male HIV–negative partners.
Conclusions The results suggest good implementation of an-
tiretroviral treatment among HIV–positive women and their 
HIV–positive partners, but no implementation, even in recent 
years, of Pre–Exposure Prophylaxis (PrEP) among uninfected 
male partners. Further studies should assess the determinants 
of this occurrence and clarify the attitudes and the potential 
barriers to PrEP use.
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The recent global HIV guidelines expanded the use of antiretroviral treatment (ART) to include ear-
ly ART before immunologic decline, pre–exposure chemoprophylaxis (PrEP), and treatment of HIV–
negative partners in serodiscordant couples [1–3]. All these situations apply to women with HIV 
who are planning a pregnancy or are already pregnant, and to their partners. An effective implemen-
tation of these measures is necessarily dependent on knowledge of HIV status in both partners, and 
a good implementation of HIV diagnosis is necessary to ensure effectiveness in the “cascade” process 
that link different steps of diagnosis and care of HIV (testing, implementation of treatment, adher-
ence with treatment, effective suppression of viral load) [4]. If both the woman and the partner are 
infected, both should be on treatment according to the expanded indications of the new guidelines, 
irrespective of the level of immunological deterioration. Treatment is however also now recommend-
ed, although less stringently, for the HIV–uninfected male partners of HIV–positive women. In this 
context, it is important to quantify to what extent the new guidelines on treatment of HIV positive 
pregnant women and their HIV positive partners, or PrEP among HIV–negative partners in serodis-
cordant couples is implemented. In order to quantify this, we used data from a large national cohort 
of pregnant women with HIV to explore temporal trends in the proportion of HIV diagnoses that 
occurred in pregnancy, maternal antiretroviral treatment at conception, prevalence of HIV infection 
among partners of HIV positive pregnant women, and proportion of seronegative and seropositive 
male partners receiving antiretroviral treatment.
METHODS
Data from the Italian National Program on Surveillance of Antiretroviral Treatment in Pregnancy were 
used [5]. This is an ongoing observational study established in Italy in 2001, which covers, based 
on available prevalence data [6], roughly 30–40% of live births from women with HIV in Italy. Site 
participation is voluntary, and at present is based on more than 30 clinicians reporting from Obstet-
rics, Infectious Diseases, and Paediatrics departments across the country. Only HIV–positive preg-
nant women are included, and treatment of HIV infection is decided by the treating physician, usu-
ally according to national guidelines. Laboratory and clinical data are collected from hospital records, 
following the women’s consent based on a patient information sheet approved by the competent Eth-
ics Committee. Information and measurements are collected at routine pregnancy visits, at delivery, 
and during a follow–up of mothers and newborns for up to 18 months. Timing of HIV diagnosis is 
calculated using the date difference between HIV diagnosis and last menstrual period. Gestational 
age at birth is determined on the basis of the last menstrual period, ultrasound biometry, or both. 
Information on HIV status of the partners is based on women’s report. Women provide consent based 
on a patient information sheet approved by the competent Ethics Committee (deliberation 578, Sep-
tember 28, 2001, I.N.M.I. Lazzaro Spallanzani Ethics Committee, Rome). For the current analysis, 
all pregnancies with available date of HIV diagnosis were considered eligible. The study period 
(2001–2015) was divided in three intervals of five years each (2001–2005, 2006–2010, 2011–2015), 
and temporal trends were analyzed using the chi–square test for trend. P values <0.05 were consid-
ered significant. All statistical analyses were performed with the SPSS software, version 22 (IBM Corp, 
released 2013, Armonk, NY, USA).
RESULTS
As of 19 August 2016, 2755 pregnancies in HIV–infected women had available information and 
were included in the analyses. The temporal trends are summarized in Table 1. Across the three time 
periods studied, the rate of HIV diagnosis in pregnancy remained stable (overall: 643/2755, 23.3%), 
with no significant changes over time (P = 0.908). Conversely, the proportion of women with HIV 
diagnosed before pregnancy who were on ART at conception increased significantly from 62.0% in 
2001–2005 (557/899), to 81.3% (312/384) in 2011–2015 (P < 0.001). Subsequent ART coverage in 
pregnancy was roughly universal, involving 99.1% (2306/2326) of the pregnancies that did not end 
early because of miscarriage, termination, or intrauterine death (proportion on ART in this group 
with no live births: 75.3%, 235/312).
The distribution of HIV status of male partners remained substantially unchanged during the entire 
period (overall: 48.7% HIV–negative, 28.6% HIV–positive and 22.8% unknown). None of the HIV–
negative partners received antiretroviral treatment during the entire time of observation, while the 
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Treatment coverage in couples with HIV and pregnancy
proportion of HIV–positive partners receiving treatment increased significantly from 73.3% in 2001–
2005 to 95.8% in 2011–2015 (P = 0.002, Table 1).
CONCLUSION
This analysis provided information on several aspects of the cascade of HIV diagnosis and treatment 
among pregnant women with HIV and their partners that can be relevant for health care providers. 
At first, we showed a stable rate of HIV diagnosis during pregnancy in the last 15 years. Although 
this rate (23%) is similar or even lower compared to other national and international studies [7,8], 
this suggests no improvement in the proportion of cases in which HIV infection was already known 
before pregnancy, a condition that represents the target for an optimal management of pregnancy. 
Similarly, no temporal changes were observed in the distribution of HIV status of the partners, with 
roughly half of the pregnancies occurring in a context of HIV–serodiscordant couples (with an HIV–
uninfected male partner), and no less than 20% of cases (overlapping the proportion of maternal 
HIV diagnosis in pregnancy) characterized by an unknown HIV status of the partner, suggesting fre-
quent occurrence of no HIV testing for both members of the couple before pregnancy. These find-
ings indicate that there is still the need to improve the rate of HIV testing among people of child-
bearing age through information campaigns and facilitated access to testing and prenatal counselling 
services. Such services should be targeted not only to women who are planning pregnancy or who 
present in early pregnancy, but also to their partners. This not only would improve management of 
pregnancy but also clinical HIV outcomes.
The analysis of temporal trends showed significant improvements in treatment coverage in the pop-
ulation with HIV already known before pregnancy. In 2011–2015, more than 80% of the women 
diagnosed before pregnancy were on treatment at conception, and almost all their HIV–positive part-
ners (95.8%) were receiving ART. These figures indicate good implementation of the expanded in-
dications to ART among people with HIV in Italy, confirming a good response to the recent guide-
lines that have progressively expanded the indication to treatment to any person with HIV, 
irrespective of the level of immune deterioration [1,2,9,10]. A wide effort is ongoing worldwide to 
ensure equal access to antiretroviral treatment to all infected people, with the aim to obtain the 90–
90–90 target (90% diagnosed, 90% treated and 90% virally suppressed), and ultimately end the HIV/
AIDS epidemics by 2030. Encouraging results have been achieved, even in countries with lower re-
sources, with more than 17 millions of people on antiretroviral treatment in 2016, although large 
disparities exist between countries [4]. Current challenges in this pathway involve reaching and di-
agnosing the millions of people who do not know that they have HIV, and effectively retaining in 
care those who start ART, in order to achieve a prolonged viral suppression [11].
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Table 1. Temporal trends in HIV and treatment status of mothers and partners (2001–2015)
2001–2015 2001–2005 2006–2010 2011–2015 P value*
Diagnosis of HIV in current pregnancy (%) 23.3 (643/2755) 22.9 (268/1172) 24.2 (261/1079) 22.6 (114/504) 0.908
Mothers on treatment at conception (%):
Overall 51.8 (1414/2728) 47.8 (557/1166) 51.0 (545/1068) 63.2 (312/494) <0.001
HIV known before pregnancy 67.6 (1414/2093) 62.0 (557/899) 67.3 (545/810) 81.3 (312/384) <0.001
HIV status of the partner† (%):
HIV–positive 28.6 (593/2077) 29.4 (262/892) 28.3 (228/807) 27.2 (103/378) 0.423
HIV–negative 48.7 (1011/2077) 50.4 (450/892) 46.0 (371/807) 50.3 (190/378) 0.562
Unknown 22.8 (473/2077) 20.2 (180/892) 25.8 (208/807) 22.5 (85/378) 0.120
HIV–positive partners on treatment† (%) 77.0 (291/378) 73.3 (121/165) 71.8 (102/142) 95.8 (68/71) 0.002
Guidelines recommendations for 
treatment in in pregnancy
Recommended (usually 
mono–or dual therapy)
Recommended 
(combination therapy)
Recommended 
(combination therapy)
Guidelines recommendations for 
treatment in all HIV–infected individuals
<200–350 CD4 or 
symptomatic disease
<350–500 CD4 or 
symptomatic disease
Progressive shift to 
any CD4 level
Guidelines recommendations for 
treatment in HIV–negative partners
Not recommended Not recommended PrEP (since 2012)
*2 for trend.
†Women with HIV infection diagnosed before pregnancy only. No HIV–negative partner was receiving anti–HIV treatment across the entire period of 
observation.
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Even more challenging may be providing treatment as prophylaxis to HIV–uninfected partners. In 
our study, none of the HIV–uninfected males in the serodiscordant couples, even in recent years, re-
ceived antiretroviral treatment as a potential prophylaxis against HIV transmission. The absence of 
any PrEP among uninfected males indicates no implementation of the recently recommended use of 
antiretroviral treatment as a preventive measure in uninfected partners. We are unable to define the 
possible basis for this occurrence, that may include preference for barrier methods compared to an-
tiretroviral treatment as preventive measures against HIV transmission in sexually active serodiscor-
dant couples, with use of self–insemination techniques (in which the woman inserts semen into the 
vagina herself, without medical intervention) when attempting to conceive. The implementation and 
efficacy of guidelines may be affected by several factors that influence the attitudes of both health 
care providers and people with HIV. The efficacy of PreP, in particular, is conditioned by adherence, 
perceived level of HIV risk, and access and availability of health services [12]. All these factors may 
show important differences among male and female heterosexuals, sex workers, men who have sex 
with men, and injection drug users [13,14]. Several studies have shown the difficulty to enrol part-
ners of HIV–infected pregnant women into programs of HIV testing and care [15,16]. Our results 
indicate the need for further studies that investigate the potential barriers to PrEP implementation 
in uninfected partners of HIV–infected women, including the specific attitudes and expectations on 
PrEP use among prescribing physicians and people with HIV.
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